Osamu Nureki
Founder at MODALIS THERAPEUTICS CORPORATION
Net worth: 1 M $ as of 30/04/2024
Profile
Osamu Nureki is the founder of Modalis Therapeutics Corp., which was founded in 2016.
He holds the title of Outside Director at the company.
He is also currently working as an Outside Director at Curreio, Inc. since 2019.
Additionally, he has been a Professor at the University of Tokyo since 2008.
Dr. Nureki completed his undergraduate and graduate degrees at the University of Tokyo.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/12/2023 | 2,266,100 ( 6.16% ) | 1 M $ | 30/04/2024 |
Osamu Nureki active positions
| Companies | Position | Start |
|---|---|---|
| MODALIS THERAPEUTICS CORPORATION | Founder | 01/01/2016 |
Curreio, Inc.
 Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Director/Board Member | 01/11/2019 |
| University of Tokyo | Corporate Officer/Principal | 01/04/2008 |
Training of Osamu Nureki
| University of Tokyo | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MODALIS THERAPEUTICS CORPORATION | Health Technology |
| Private companies | 1 |
|---|---|
Curreio, Inc.
Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Health Technology |
- Stock Market
- Insiders
- Osamu Nureki
